Liquid Biopsies, What We Do Not Know (Yet)

Alberto Bardelli; Klaus Pantel

doi:10.1016/j.ccell.2017.01.002

Liquid Biopsies, What We Do Not Know (Yet)

Alberto Bardelli, Klaus Pantel

Istituto Oncologico Candiolo

Research output: Contribution to journal › Review article › peer-review

Abstract

The inherent molecular heterogeneity of metastatic tumors and the ability of cancer genomes to dynamically evolve are not properly captured by tissue specimens. Analysis of cell-free DNA and circulating tumor cells has the potential to change clinical practice by exploiting blood rather than tissue as a source of information. Liquid biopsies are already used to monitor disease response and track the emergence of drug resistance. The suitability of blood-based molecular profiles for early detection and monitoring minimal residual disease is being evaluated. In this review, we address open questions in this fast-evolving field of research.

Original language	English
Pages (from-to)	172-179
Number of pages	8
Journal	Cancer Cell
Volume	31
Issue number	2
DOIs	https://doi.org/10.1016/j.ccell.2017.01.002
Publication status	Published - Feb 13 2017

ASJC Scopus subject areas

Oncology
Cell Biology
Cancer Research

Access to Document

10.1016/j.ccell.2017.01.002

Fingerprint Dive into the research topics of 'Liquid Biopsies, What We Do Not Know (Yet)'. Together they form a unique fingerprint.

Cite this

@article{91fde10288154930b5e870a6baca2011,

title = "Liquid Biopsies, What We Do Not Know (Yet)",

abstract = "The inherent molecular heterogeneity of metastatic tumors and the ability of cancer genomes to dynamically evolve are not properly captured by tissue specimens. Analysis of cell-free DNA and circulating tumor cells has the potential to change clinical practice by exploiting blood rather than tissue as a source of information. Liquid biopsies are already used to monitor disease response and track the emergence of drug resistance. The suitability of blood-based molecular profiles for early detection and monitoring minimal residual disease is being evaluated. In this review, we address open questions in this fast-evolving field of research.",

author = "Alberto Bardelli and Klaus Pantel",

year = "2017",

month = feb,

day = "13",

doi = "10.1016/j.ccell.2017.01.002",

language = "English",

volume = "31",

pages = "172--179",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "2",

}

TY - JOUR

T1 - Liquid Biopsies, What We Do Not Know (Yet)

AU - Bardelli, Alberto

AU - Pantel, Klaus

PY - 2017/2/13

Y1 - 2017/2/13

N2 - The inherent molecular heterogeneity of metastatic tumors and the ability of cancer genomes to dynamically evolve are not properly captured by tissue specimens. Analysis of cell-free DNA and circulating tumor cells has the potential to change clinical practice by exploiting blood rather than tissue as a source of information. Liquid biopsies are already used to monitor disease response and track the emergence of drug resistance. The suitability of blood-based molecular profiles for early detection and monitoring minimal residual disease is being evaluated. In this review, we address open questions in this fast-evolving field of research.

AB - The inherent molecular heterogeneity of metastatic tumors and the ability of cancer genomes to dynamically evolve are not properly captured by tissue specimens. Analysis of cell-free DNA and circulating tumor cells has the potential to change clinical practice by exploiting blood rather than tissue as a source of information. Liquid biopsies are already used to monitor disease response and track the emergence of drug resistance. The suitability of blood-based molecular profiles for early detection and monitoring minimal residual disease is being evaluated. In this review, we address open questions in this fast-evolving field of research.

UR - http://www.scopus.com/inward/record.url?scp=85012886951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012886951&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2017.01.002

DO - 10.1016/j.ccell.2017.01.002

M3 - Review article

C2 - 28196593

AN - SCOPUS:85012886951

VL - 31

SP - 172

EP - 179

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 2

ER -